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Available online xxxxChronic presence ofmutant,misfolded proteins in the endoplasmic reticulum (ER) initiates ER stress and induces
the Unfolded Protein Response (UPR).
In Gaucher disease (GD), resulting frommutations in theGBA1 gene, encoding lysosomal acid β-glucocerebrosidase
(GCase), a certain fraction of the mutant variants is retained in the ER and activates the UPR. We have previously
shownUPR activation inGDderivedﬁbroblasts, inﬁbroblasts that derived from carriers of GDmutations and inDro-
sophilamodels of carriers of GD mutations.
In the present work we extended our studies to include a large collection of ﬁbroblasts, EBV-transformed B-cells
and white blood cells (WBCs) that derived from GD patients.
The results showed UPR activation in all tested cells. They also indicated that transcription of the GBA1 gene is
upregulated through activation of the UPR-induced CHOP transcription factor. Transcription of the MAN2B
gene, encoding alpha-mannosidase and of the ACP gene, encoding acid phosphatase was also elevated presum-
ably through CHOP activation.
Our results highlight the existence of chronic stress in GDderived cells due to the presence of ER-retainedmutant
GCase, which leads to upregulation of GBA1 expression.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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CHOP1. Introduction
Gaucher disease (GD), an autosomal recessive genetic disorder, re-
sults mainly from mutations in the GBA1 gene (OMIM #606463),
encoding acid β-glucocerebrosidase (GCase; EC 3.2.1.45) [1]. Mutations
in the saposin C domain of the prosaposin gene (PSAP) also result in GD
[2–4]. Presence of mutant enzyme leads to decreased lysosomal activity
and accumulation of the substrate glucosylceramide (glucocerebroside)
[1]. More so, a certain fraction of the mutant enzyme is retained in the
ER and undergoes ER associated degradation (ERAD) [5]. The chronic
presence of mutant enzyme in the ER leads to ER stress and upregulates
the Unfolded Protein Response (UPR), a cascade of signaling pathways
aiming at reaching homeostasis in the cells. If not achieved, the cells
undergo apoptotic death. The ER membrane harbors three ER stress
sensors: the type 1 transmembrane protein kinase endoribonuclease
(IRE1), the type 1 protein kinase (PERK), and the activating transcrip-
tion factor 6 (ATF6). These three UPR transducers are constitutivelyrch and Immunology, Tel Aviv
).
. This is an open access article under
l., Blood Cells Mol. Diseases (2expressed in metazoan cells, and are maintained in an inactive state
through interaction with the ER chaperone BiP (Immunoglobulin
heavy chain-binding protein) [6,7]. ER-accumulated unfolded proteins
bind and sequester BiP, thus promoting its dissociation from PERK,
IRE1 and ATF6. Dissociation of BiP from the three stress sensors allows
their modiﬁcation and activation, which results in a response to the ac-
cumulation ofmisfolded proteins [7–9]. Thus, IRE1 undergoes dimeriza-
tion and phosphorylation, and participates in a cytoplasmic complex,
which splices the transcription factor X-box binding protein 1 (Xbp1).
Upon its splicing the Xbp1 mRNA (Xbp1s) is translated into a protein
that translocates into the nucleus and activates UPR related genes
[10–13]. PERK is a kinase that undergoes dimerization and autophos-
phorylation, and mediates phosphorylation of the eukaryotic transla-
tion initiation factor 2α (eIF2α) [8]. Phosphorylated eIF2α attenuates
general protein translation in the cells [7,8,12,14,15]. Modiﬁed PERK
also initiates translation of ATF4, which activates transcription of UPR
related genes, like the CAAT/Enhancer binding protein (C/EBP) homol-
ogous protein (CHOP), which is a proapoptotic bZIP transcription factor
[16,17]. CHOP is essential for cell cycle arrest as part of the apoptotic re-
sponse to chronic ER stress [6,14,18]. ATF6 shuttles to the Golgi, where
it is sequentially cleaved by proteases. Its cleaved N-terminal cytosolicthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1
Primers used in this study. The table contains the sequence of all the primers used in this
work. RT = real time, R = reverse, F = forward.
Primer Primer sequence
Human-GAPDH-RT-F 5′-CTCCTCCTGTTCGACAGTCA-3′
Human-GAPDH-RT-R 5′-GTTGACTCCGACCTTCACCT-3′
Human-CHOP-RT-F 5′-AGCGACAGAGCCAAAATCAG-3′
Human-CHOP-RT-R 5′-TCTGCTTTCAGGTGTGGTGA-3′
Human-BiP-RT-F 5′-CATCAAGTTCTTGCCGTTCA-3′
Human-BiP-RT-R 5′-ATGTCTTTGTTTGCCCACCT-3′
Human-ATF4-RT-F 5′-GTTCTCCAGCGACAAGGCTA-3′
Human-ATF4-RT-R 5′-ATCCTGCTTGCTGTTGTTGG-3′
Human-GBA1-RT-F 5′-AGGCAGTGTCGTGGGCAT-3′
Human-GBA1-RT-R 5′-ACCAAGGGCAGGAAAGGT-3′
Human-MAN2B-RT-F 5′-GATCATTGGACAAGCCAGAC-3′
Human-MAN2B-RT-R 5′-CGTCTGCCCTATTTACCCAT-3′
Human-ACP-RT-F 5′-AACCTAAACCAGCAGCCATC-3′
Human-ACP-RT-R 5′-AGCACATCAAGATCATGGGA-3′
Human-GAPDH-F 5′-CCATCAATGACCCCTTCATTGACC-3′
Human-GAPDH-R 5′-CTCAYGGYYCACACCCATGAC-3′
Human-Xbp1s-F 5′-TCTGCTGAGTCCGCAGCAG-3′
Human-Xbp1s-R 5′-GAAAAGGGAGGCTGGTAAGGAAC-3′
2 H. Braunstein et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxfragment serves as a transcription factor of UPR upregulated genes [7,
11,12,14,19].
Activation of UPR in GDderived cells has already been noted inﬁbro-
blast lines that originated from GD patients, homozygous for the N370S
or the L444P mutations [20,21]. We documented it in several ﬁbroblast
lines that derived from GD patients and carriers of GD mutations by
assaying the increase in BiP and CHOPmRNAs and proteins, the increase
in Xbp1 splicing and phosphorylation of eIF2α [22]. Accumulation of
glucosylceramide per se, induced by conduritol-β-epoxide (CBE), did
not result in UPR [22]. Likewise, in the absence of mutant GCase there
was no UPR [23], underscoring the importance of mutant GCase in the
activation of UPR.
GDpatients and carriers of GDmutations have a higher propensity to
develop Parkinson disease (PD) than the non-GD population [24]. We
and others have shown that the presence of mutant GCase activates
UPR and leads to development of parkinsonian signs or neurodegener-
ation in Drosophila melanogaster [22,25,26].
It has already been documented that GBA1 mRNA levels are in-
creased in GD derived cells, the nature of which was unknown
[27]. Previous studies indicated that a 630 bp promoter fragment
of the human GBA1 gene was sufﬁcient to confer the same tissue
speciﬁcity as the entire gene. This fragment contains 365 bp up-
stream the transcription start site and 265 bp of the ﬁrst exon [27,
28]. Using Electrophoretic Mobility Shift Assays (EMSAs) and Chlor-
amphenicol Acetyl Transferase (CAT) assays our lab showed that
OCTA binding protein (OBP), activator protein 1 (AP-1), polyoma
enhancer activator 3 (PEA3) and a CAAT enhancer binding protein
(C/EBP) participate in regulating the GBA1 gene [29].
In the present study we document activation of UPR in GD derived
cultured ﬁbroblasts, in cultured lymphoblasts and in white blood cells
(WBCs) fromGD patients.We also show that the increase in GBA1 tran-
scription in GD-derived cells is mediated by the UPR-activated CHOP
protein.
2. Materials and methods
2.1. Cell lines
Human primary skin ﬁbroblasts andEBV-transformed B-cells derived
fromGD patients and carriers were from the “Cell Line and DNA Biobank
from Patients Affected by Genetic Diseases” (G. Gaslini Institute). Skin
ﬁbroblasts (cultured ﬁbroblasts) were grown in DMEM supplemented
with 20% FBS (Biological Industries, Beit Haemek, Israel). Human EBV
transformed B-cells (cultured lymphoblasts) were grown in RPMI sup-
plemented with 10–20% FBS (Biological Industries, Beit Haemek, Israel).
HEK293 (Human epithelial embryonic kidney) cells were grown in
DMEM supplemented with 10% FBS. All cells were grown at 37 °C in
the presence of 5% CO2.
2.2. Antibodies
The following primary antibodies were used in this study: rabbit
polyclonal anti-phospho-eIF2α (Ser51) antibodies, rabbit polyclonal
anti-eIF2α antibodies (from cell signaling Technology, Beverly, MA,
USA), Rabbit polyclonal anti-ERK antibodies (Santa Cruz Biotechnology,
CA, USA) and mouse monoclonal anti-myc antibody (Cell Signaling
Technology, Beverly, MA, USA).
Secondary antibodies used were: horseradish peroxidase-conju-
gated goat anti-mouse antibodies and horseradish peroxidase-con-
jugated goat anti-rabbit antibodies (both from Jackson Immuno
Research Laboratories, West Grove, PA, USA).
2.3. Chemicals
Leupeptin, phenylmethylsulfonyl ﬂuoride (PMSF), aprotinin and
phosphatase inhibitor cocktails 2 and 3 were from Sigma-AldrichPlease cite this article as: H. Braunstein, et al., Blood Cells Mol. Diseases (2(Rehovot, Israel). KAPA SYBR FAST UNIVERSAL qPCR kit was from
KAPA Biosystems Inc. (Wilmington, MA, USA). CBE and thapsigargin
were from Sigma-Aldrich (Rehovot, Israel).
2.4. Plasmids
pGL3-N: A 630 bp normal human GBA1 promoter fragment, pre-
pared by cleavage of an existing clone [24] with the restriction enzyme
SacI, was introduced into the SacI restriction site of themammalian vec-
tor pGL3 (Promega Corporation,Madison,WI, USA), harboring the lucif-
erase gene.
pGL3-M: The above mentioned vector, harboring a 630 bp human
GBA1 promoter fragment, mutated at its CHOP binding site (CCAAT→
CTGGC).
pGL2: A mammalian vector expressing the renilla gene coupled to
the CMV promoter (Promega Corporation, Madison, WI, USA).
pcDNA4-myc-His-CHOP: CHOP sequence was ampliﬁed from a
human cDNA library, prepared from a normal ﬁbroblast line
(F0908, kindly provided by Prof. Eli Sprecher, Department of Derma-
tology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel), using the
primers: CHOP cDNA-F: TTAGCGGAATTCATGGCAACT and CHOP
cDNA-R: TCCAATCTCGAGATTGCTTGG. The 1028 bp ampliﬁed CHOP
cDNA fragment, which contained EcoRI and XhoI restriction sites on
its 5′ and 3′ ends, respectively (appears in bold), was cloned
between the EcoRI and XhoI restriction sites of pcDNA4-myc-His-
plasmid (Invitrogen Life Technologies Co., Carlsbad, CA, USA).
2.5. Separation of WBCs from whole blood
Pellets of WBCs were isolated by applying whole blood samples on
polysucrose sodium metrizoate in UNI-SEP lymphocyte separation
tubes (Novamed, Jerusalem, Israel) and processed according to the
manufacturer's instructions.
2.6. Patients' genotypes
Molecular characterization of the samples used in the present
study was performed at the Gaslini Institute (Genoa, Italy) on ﬁbro-
blasts and EBV transformed B-cells and at Shaare Tzedek Hospital
(Jerusalem, Israel) on patients' derived blood samples.
Since the traditional amino-acid residue numbering, which excludes
the ﬁrst 39 amino acids of the leader sequence (GenBank accession
GBA1 no. NP_000148.2) is regularly used in GD literature and not the016), http://dx.doi.org/10.1016/j.bcmd.2016.10.025
3H. Braunstein et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxrecommended nomenclature (http://www.hgvs.org/mutnomen), we
used it in the present study.
2.7. RNA extraction and Reverse Transcription (RT)
Total RNA was isolated from cell pellets using TRIZOL reagent
(Life-technologies Co. Carlsbad, CA, USA) according to the
manufacturer's instructions. One microgram of RNA was reverse
transcribed with M-MLV reverse transcriptase (Promega Corpora-
tion, CA, USA), using oligo-dT primer in a total volume of 25 μl, atR
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Fig. 1.UPR activation in GD cultured ﬁbroblasts. a. Quantitative RT-PCR of BiP and CHOPmR
results obtained for 13 samples. c. Quantiﬁcation of results (for 14 cultured ﬁbroblasts) as
The results are themean± SEM of ﬁve independent experiments. d. Protein lysates were pr
interacted with anti p-eIF2α antibodies and as a loading control, with anti eIF2α antibod
shown in d. The blots were quantiﬁed by dividing the amount of p-eIF2α by that of tota
results are the mean ± SEM of three independent experiments. Signiﬁcance: * b0.05; ** b
Please cite this article as: H. Braunstein, et al., Blood Cells Mol. Diseases (242 °C for 60 min. Reactions were stopped by incubation at 70 °C for
15 min.
2.8. PCR
Two microliters of the cDNA mixture were ampliﬁed by PCR in
Red Load Taq Master ×5 buffer (Larova, Germany), carried out for
35 cycles by denaturing at 94 °C for 30 s, annealing at 52 °C for
30 s, and extending at 72 °C for 30 s. PCR reactions were carried out
in an Eppendorff Master-cycler EP Gradient S (Eppendorf, Hamburg,notype
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NAs. b. RT-PCR of spliced Xbp1mRNA isolated from 14 cultured ﬁbroblasts. Shown are
presented in b. The columns in the graph appear beneath the corresponding gel lanes.
epared from 14 GD cultured ﬁbroblasts and subjected to western blotting, whichwere
ies. Shown are results from 8 out of 14 tested samples. e. Quantiﬁcation of results as
l-eIF2α in the same lane. Values obtained for normal cell line was considered 1. The
0.01.
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4 H. Braunstein et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxGermany). RT-PCR products were separated through 1% agarose gels
and visualized with 0.1% ethidium bromide. Sequence of the primers
used is listed in Table 1.2.9. Detection of Xbp1 mRNA splicing
Human spliced Xbp1was ampliﬁed from cDNA using the primers:
Human Xbp1s-F and Human Xbp1s-R (Table 1). These primers allow
ampliﬁcation of the spliced Xbp1 cDNA only. GAPDH (Glyceraldehyde
3-phosphate dehydrogenase) was used as a normalizing control
(ampliﬁed with primers: Human-GAPDH-F and Human-GAPDH-R,
Table 1).2.10. Quantitative real time (qRT) PCR
PCR ampliﬁcationwas performed using the KAPA SYBR FASTUNIVER-
SAL qPCR kit in a Rotor-Gene 6000 thermal cycler (Qiagen, Hilden,
Germany). The reaction was executed in 10 μl containing 1.5 μl of cDNA
(diluted 1:64), 10ρmol of each primer and 5 μl SYBRmix. Thermal cycling
conditionswere: 95 °C (10min), and 40 cycles of 95 °C (10 s), 60 °C (20 s)
and 72 °C (20 s). Each sample was loaded in triplicate. The quantitative
analysis was performed using the Rotor-Gene 6000 Series software
(Qiagen, Hilden, Germany) and relative gene expression was determined
by the Ct value. The resultswere quantiﬁedbydividing the value obtained
for each sample by that obtained for GAPDH (as a normalizing gene).
Values obtained for the cDNA that derived from the normal cell line was
considered 1. Sequence of the primers used appears in Table 1.2.11. SDS-PAGE and western blotting
Cell monolayers or cell pellets were washed three times with ice-
cold phosphate-buffered saline (PBS) and lysed at 4 °C in lysis buffer
(20 mM TRIS HCL pH, 7.5, 100 mM NaCl, 1 mM MgCl2, 5 mM EDTA
and 0.5% NP-40) containing 10 μg/ml aprotinin, 0.1 mM PMSF,
10 μg/ml leupeptin and 1% phosphatase inhibitor cocktails 2 and 3.
Lysates were incubated on ice for 30 min and centrifuged at 10,000 g
for 15 min at 4 °C. The lysates were electrophoresed through 10% SDS-
PAGE, after which the corresponding blots were interacted with anti-
bodies. The blots were scanned using Image Scan scanner (Amersham
Pharmacia Biotech, Buckinghamshire, England), and the intensity of
each band was measured by the Image Master 1DPrime densitometer
(Amersham Pharmacia Biotech, Buckinghamshire, England) and
GelQuant (BiochemLabSolutions, California).Table 2
UPR activation in culturedﬁbroblasts fromGDpatients. Values represent themean±SEMof thr
experiments. Signiﬁcance: ⁎ b0.05; ⁎⁎ b0.01. N.T.—Not Tested. §All GBA1mutations are describe
amino acids of the leader sequence (GBA1 GenBank accession NM_000157.3; NP_000148.2).
Genotype§ GD type Relative CHOPmRNA
Normal – 1
Normal – 0.9 ± 0.12
[N370S] + [R120W] 1 5.5 ± 2.4⁎
[NS370S] + [D399N] 1 2.1 ± 0.8
[N370S] + [N370S] 1 3.4 ± 1.3⁎
[N370S] + [RI3IC] 1 7.9 ± 3.3⁎
[N370S + [L444P] 1 6.7 ± 0.6⁎⁎
[N370S] + [RecNcil] 1 4.8 ± 1.1⁎⁎
[N370S] + [I199S] 1 7.6 ± 2.6⁎
[IVS8(-11delC)(-14TNA)] + [R170P] 1 3.9 ± 1.8⁎
[L444P] + [W312S] 1 2.1 ± 0.6⁎
[D409H;H225Q] + [D409H;H225Q] 2 2.6 ± 0.5⁎⁎
[NI88K] + [Δ55] 2 3.5 ± 1.8⁎
[N188S] + [S107L] 3 4.0 ± 0.5⁎⁎
[L444P] + [F213I] 3 2.3 ± 0.5⁎
[L444P;E326K] + [L444P;E326K] 3 4.4 ± 1⁎
Please cite this article as: H. Braunstein, et al., Blood Cells Mol. Diseases (22.12. Transfections and reporter assays
HEK293 cells were transfected using calcium phosphate solutions. A
mixture of DNA in 250 μl of 250 mM CaCl2 was dropped into a tube
containing HBSX2 solution (50 mM Hepes, 280 mM NaCl, 1.5 mM
Na2HPO4, pH 7.09) and incubated for 20 min at RT. The mixture was
then added dropwise to subconﬂuent cells. Forty‐eight hours later, cell
lysates were prepared and luciferase activity was tested using the
Dual-Luciferase Reporter Assay System according to themanufacturer's
instructions (Promega Corporation, Madison, WI, USA). Samples were
analyzed in a Veritas GloMax-96 Microplate Luminometer (Promega
Corporation, Madison, WI, USA).
2.13. Statistical analysis
All the results were statistically analyzed using the student t-test.
3. Results
3.1. Activation of UPR in GD derived cells
Certain fraction of mutant GCase is retained in the ER and undergoes
ERAD [5]. The chronic presence of mutant GCase in the ER leads to ER
stress, which activates the UPR. We have previously shown activation
of UPR in GD derived ﬁbroblasts as well as in ﬁbroblasts that derived
from carriers of GBA1mutations [22]. In the present work we extended
our previous studies to show that in different patients, somewithmuta-
tions distinct from those we described before, there is UPR activation.
For UPR activation in GD derived ﬁbroblasts, mRNA levels of BiP and
CHOP, mRNA levels of spliced Xbp1 (Xbp1s) and protein levels of phos-
phorylated translation initiation factor eIF2α were tested. The results
(Fig. 1, Table 2) showed that UPR is activated in all tested GD derived ﬁ-
broblasts. The same experiments were carried out in two other sample
types, EBV-transformed B-cells and WBCs, derived directly from pa-
tients. The results, presented in Fig. 2 and Table 3, showed elevation in
BiP and CHOPmRNA levels as well as elevation in Xbp1 splicing (tested
by a set of primers that amplify only the spliced form of Xbp1 mRNA,
designated Xbp1s). No signiﬁcant elevation in phosphorylation of
eIF2α was observed, likely due to EBV transformation. These results
strongly indicated activation of UPR in cultured lymphoblasts. In
WBCs elevation in mRNA levels of BiP, CHOP and ATF4 was tested
(Fig. 3, Table 4). Due to sample size constrains we were unable to test
phosphorylation of eIF2α using western blotting. Therefore, instead of
phosphorylation of eIF2α, the increase in transcription of ATF4 in the
PERK armof UPRwas tested, using quantitative RT-PCR [12]. Our results
indicated activation of UPR in WBCs.ee (for eIF2a) orﬁve (qRT-PCR forBiP and CHOPmRNAs,Xbp1mRNA splicing) independent
d according to the traditional amino-acid residue numbering, which excludes the ﬁrst 39
Relative BiPmRNA Relative Xbp1mRNA splicing Relative p-eIF2α
1 1 1
1.04 ± 0.1 0.97 ± 0.08 N.T.
4.6 ± 1.9⁎ 2.4 ± 0.47⁎ 1.5 ± 0.05⁎⁎
2.2 ± 0.7⁎⁎ 1.9 ± 0.42⁎ 2.1 ± 0.23⁎⁎
7.8 ± 2.5⁎ 2.6 ± 0.61⁎ 2 ± 0.25⁎
3.8 ± 2.1⁎ 1.6 ± 0.16⁎ 1.8 ± 0.41⁎
5.2 ± 0.9⁎⁎ 1.6 ± 0.22⁎ 2.5 ± 0.72⁎
1.6 ± 0.2⁎ 1.6 ± 0.08⁎⁎ 2.1 ± 0.68⁎
6 ± 2.7⁎ 1.9 ± 0.21⁎⁎ 1.6 ± 0.17⁎
2 ± 0.6⁎ 1.8 ± 0.14⁎⁎ 2 ± 0.24⁎⁎
2.7 ± 1.2⁎ 2 ± 0.53⁎ 1.9 ± 0.64⁎
2.2 ± 0.3⁎⁎ 1.9 ± 0.34⁎⁎ 2.5 ± 0.5⁎
5.1 ± 2.2⁎ 1.8 ± 0.19⁎ 2.1 ± 0.34⁎⁎
4.3 ± 1.5⁎⁎ 2 ± 0.4⁎ 2 ± 0.12⁎⁎
2.7 ± 1.3⁎ 2 ± 0.45⁎ 2 ± 0.44⁎
3.7 ± 1.3⁎⁎ 1.5 ± 0.23⁎ 1.5 ± 0.21⁎
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Fig. 2. UPR activation in GD EBV Transformed B-cells. a. Quantitative RT-PCR of BiP and CHOPmRNA. b. Protein lysates were prepared from different GD derived cultured B-cells and
subjected to western blotting, which were interacted with anti p-eIF2α antibodies and as a loading control, with anti eIF2α antibodies. c. RT-PCR of spliced Xbp1mRNA. Shown are 4
out of 6 tested samples. GAPDH was used as a normalizing control. d. Quantiﬁcation of results as shown in c. Results are the mean ± SEM of ﬁve independent experiments.
Signiﬁcance: * b0.05; ** b0.01.
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different cell types that derived fromGD patients (skin ﬁbroblasts, EBV-
transformed B cells and whiteWBCs) and highlight its generality in GD.3.2. Upregulation of GBA1 transcription due to UPR activation
We have shown in the past that GBA1mRNA levels are elevated in
GD derived cell lines [27]. We wrote then that: “comparison of the
GCase mRNA levels in Gaucher-versus non-Gaucher-derived cells re-
vealed that in Gaucher cells this RNA is always more abundant than in
the corresponding non-Gaucher counterparts, suggesting the involve-
ment of a feed-back mechanism sensitive to the levels of actual enzy-
matic activity” [27]. In the present study, we revisited this topic and
conﬁrmed the data by performing quantitative RT-PCR on RNA that de-
rived from GD derived ﬁbroblasts, from ﬁbroblasts that originated from
carriers of GD mutations, (Fig. 4a), from EBV transformed B-cells (Fig.
4b) and fromWBCs that derived from GD patients (Fig. 4c). The results
showed that GBA1mRNA level was elevated in all tested cells, that de-
rived from GD patients or from carriers of GDmutations, in comparison
to non GD cells.Table 3
UPR activation in EBV transformed B-Cells fromGDpatients. Values represent themean±SEMo
mutations are described according to the traditional amino-acid residue numbering, which
NM_000157.3; NP_000148.2).
Genotype§ GD type Relative CHOPmRNA
Normal – 1
Normal – 1.03 ± 0.1
[N370S] + [D399N] 1 3.97 ± 1.75⁎
[N370S] + [F213I] 1 2.66 ± 0.94⁎
[G202R] + [G202R] 2 9.2 ± 3.04⁎
[T231R] + [?] 2 2.95 ± 0.35⁎
[D409H;H225Q] + [D409H;H225Q] 3 7.26 ± 0.77⁎⁎
[D409H] + [?] 3 2.2 ± 0.35⁎
Please cite this article as: H. Braunstein, et al., Blood Cells Mol. Diseases (2Accumulation of glucosylceramide per se, induced by CBE, a non-
competitive inhibitor of all cellular GCases, did not result in UPR activa-
tion. We tested whether this accumulation has an effect on GBA1 tran-
scription. Treatment of normal skin ﬁbroblasts for 10 days with
200 mM CBE, did not induce elevation in GBA1mRNA levels (Fig. 4a),
strongly suggesting that UPR activation, induced by presence of mutant
GCase and not by glucosylceramide accumulation, leads to upregulation
of GBA1 transcription.
Based on our results, showing thatGBA1 transcription is upregulated
in GD derived cells, which also present activation of UPR, we tested
whether UPR modulates GBA1 expression. To do so, we treated cells
with thapsigargin. Thapsigargin is a non-competitive inhibitor of the
sarco/endoplasmic reticulum Ca+2 ATPase (SERCA), which causes a de-
crease in ER calcium level. This decrease in ER calcium level decelerates
activity of calcium-dependent ER chaperones and increases the amount
of unfolded proteins in the ER [30]. Thapsigargin also inhibits fusion of
autophagosomes with lysosomes, which also induces stress on the ER
and activates the UPR [31]. Two hours of treatment with thapsigargin
(Fig. 5a) signiﬁcantly increased transcription of the GBA1 gene in both
normal and GD derived ﬁbroblasts, strongly suggesting that UPR activa-
tion leads to elevation in GBA1 transcription.fﬁve independent experiments. Signiﬁcance: ⁎ b0.05; ⁎⁎b0.01. N.T.—Not Tested. §AllGBA1
excludes the ﬁrst 39 amino acids of the leader sequence (GBA1 GenBank accession nos.
Relative BiPmRNA Relative Xbp1mRNA splicing Relative p-eIF2α
1 1 1
0.92 ± 0.09 1.1 ± 0.11 N.T.
3.15 ± 0.51⁎ 2.08 ± 0.23⁎ 0.98 ± 0.12
4.02 ± 0.57⁎⁎ 2.25 ± 0.29⁎ 0.93 ± 0.18
4.83 ± 2.38⁎ 1.81 ± 0.15⁎⁎ 1.04 ± 0.15
3.03 ± 0.3⁎ 2.42 ± 0.6⁎ 1.05 ± 0.06
3.75 ± 0.34⁎⁎ 2.33 ± 0.26⁎ 0.9 ± 0.15
1.76 ± 0.18⁎ 2.28 ± 0.44⁎ 1.1 ± 0.14
016), http://dx.doi.org/10.1016/j.bcmd.2016.10.025
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The transcription factor CHOP is upregulated as part of UPR activa-
tion [8,15]. CHOP is a nuclear protein of the C/EBP family of transcription
factors. This family was ﬁrst shown to bind the “CCAAT” DNA element
and to regulate a variety of genes involved in a broad range of physio-
logical processes, including immune functions as well as cell differenti-
ation and proliferation [32].
The GBA1 promoter contains a “CCAAT” site, which binds C/EBP, as
we have shown in the past, using EMSA and DNAse footprinting assays
[29]. Since CHOP is a member of the C/EBP family [32], we decided to
test whether activation of GBA1 transcription in GD-derived cells resultsTable 4
UPR activation in WBCs from GD patients. Values represent the mean ± SEM of ﬁve
independent experiments. Signiﬁcance: ⁎ b0.05; ⁎⁎ b0.01. §All GBA1 mutations are de-
scribed according to the traditional amino-acid residue numbering, which excludes the
ﬁrst 39 amino acids of the leader sequence (GBA1 GenBank accession NM_000157.3;
NP_000148.2).
Genotype§ GD type Relative CHOP
mRNA
Relative BiP
mRNA
Relative ATF4
mRNA
Normal – 1 1 1
Normal – 0.93 ± 0.14 1.12 ± 0.15 0.97 ± 0.06
[N370S] + [N370S] 1 2.32 ± 0.53⁎ 1.72 ± 0.28⁎ 3.45 ± 0.64⁎
[N370S] + [N370S] 1 2.22 ± 0.21⁎ 1.64 ± 0.14⁎ 2.46 ± 0.24⁎⁎
[N370S] + [N370S] 1 4.14 ± 0.78⁎ 2.1 ± 0.39⁎ 5.2 ± 1.35⁎
[N370S] + [N370S] 1 1.6 ± 0.18⁎ 3.68 ± 0.7⁎ 3.33 ± 0.5⁎
[N370S] + [N370S] 1 2.58 ± 0.6⁎ 1.8 ± 0.21⁎ 3.33 ± 0.66⁎
[N370S] + [N370S] 1 1.81 ± 0.31⁎ 2.73 ± 0.26⁎⁎ 3.81 ± 0.9⁎
[N370S] + [N370S] 1 3.57 ± 0.75⁎ 3 ± 0.6⁎ 2 ± 0.21⁎
[N370S] + [N370S] 1 3.38 ± 0.54⁎ 2 ± 0.31⁎ 4.72 ± 0.61⁎⁎
[N370S] + [N370S] 1 3.22 ± 0.76⁎ 2 ± 0.29⁎ 2.88 ± 0.5⁎
[N370S] + [N370S] 1 2.76 ± 0.35⁎ 2 ± 0.15⁎⁎ 3.78 ± 0.6⁎
[N370S] + [N370S] 1 3.57 ± 0.9⁎ 3.5 ± 0.58⁎ 3.34 ± 0.58⁎
[N370S] + [N370S] 1 3.4 ± 0.6⁎ 4 ± 0.8⁎ 2.7 ± 0.5⁎
[N370S] + [84GG] 1 2.03 ± 0.33⁎ 1.97 ± 0.27⁎ 1.98 ± 0.35⁎
[N370S] + [84GG] 1 1.78 ± 0.25⁎ 1.71 ± 0.22⁎ 2.23 ± 0.35⁎
[N370S] + [84GG] 1 3.86 ± 0.9⁎ 3 ± 0.5⁎ 3.33 ± 0.43⁎
[N370S] + [84GG] 1 1.5 ± 0.13⁎ 3.5 ± 0.68⁎ 2.5 ± 0.3⁎
[N370S] + [L444P] 1 2.2 ± 0.37⁎ 1.98 ± 0.24⁎ 2.89 ± 0.65⁎
[N370S] + [L444P] 1 2.14 ± 0.35⁎ 1.88 ± 0.2⁎ 4.73 ± 1.05⁎
[N370S] + [L444P] 1 3.97 ± 0.66⁎ 4 ± 0.78⁎ 3.15 ± 0.8⁎
[N370S] + [R496H] 1 2.2 ± 0.21⁎ 1.41 ± 0.1⁎ 2.72 ± 0.56⁎
[N370S] + [R496H] 1 1.54 ± 0.15⁎ 1.72 ± 0.24⁎ 2.25 ± 0.4⁎
[N370S] + [V394L] 1 2.25 ± 0.35⁎ 1.51 ± 0.11⁎ 2.39 ± 0.46⁎
[N370S] + [V394L] 1 2.33 ± 0.26⁎ 1.43 ± 0.12⁎ 1.5 ± 0.11⁎
[N370S] + [V394L] 1 3.58 ± 0.44⁎⁎ 1.85 ± 0.23⁎ 3.45 ± 0.6⁎
[N370S] + [IVS2 + 1] 1 4.11 ± 0.76⁎ 2.5 ± 0.5⁎ 3.75 ± 0.9⁎
[R48W] + [RecTL] 1 2.5 ± 0.57⁎ 1.56 ± 0.1⁎ 2.88 ± 0.35⁎
[R496H] + [84GG] 1 1.5 ± 0.12⁎ 3 ± 0.44⁎ 3.48 ± 0.77⁎
[R496H] + [84GG] 1 3.37 ± 0.5⁎⁎ 2 ± 0.26⁎ 2.5 ± 0.4⁎
[V394 L] + [L444P] 1 2.16 ± 0.43⁎ 2.4 ± 0.34⁎ 4 ± 1⁎
Please cite this article as: H. Braunstein, et al., Blood Cells Mol. Diseases (2from UPR-mediated increase in CHOP levels. To do this, we tested the
direct effect of CHOP on the 630 bp normal GBA1 promoter fragment
as well as its effect on a promoter fragment mutated in its “CCAAT”
binding site (CCAAT→ CTGGC, Fig. 5b). We used both promoter frag-
ments in the past to show binding of C/EBP to the “CAAT” consensus
site [28,29]. As evident from the results (Fig. 5c), CHOP increased
luciferase activity directed by the normal GBA1 promoter but not by a
GBA1 promoter mutated in its CHOP binding site. CHOP expression
was conﬁrmed by western blotting (Fig. 5d). Our results strongly sug-
gest that UPR-activated CHOP upregulates GBA1 transcription.
Several publications reported elevated activities of lysosomal en-
zymes in serum from GD patients. These included α-mannosidase and
acid phosphatase [33,34]. We wondered whether this elevation reﬂects
activation of the corresponding genes. Our results, presented in Supple-
mentary Fig.1, indicated that there is an elevation in theMAN2B and ACP
mRNA levels in all GD tested ﬁbroblast lines as well as inWBCs. This el-
evation may have resulted from UPR-mediated CHOP activation.
4. Discussion
In the present study we conﬁrm UPR activation in ﬁbroblasts,
EBV-transformed B-cells and fresh WBCs derived from GD patients
with different genotypes. We also show UPR-modulated activation
of GBA1 mRNA expression through the transcription factor CHOP.
Several previous publications documented UPR activation in GD
derived skin ﬁbroblasts [35–37]. Our lab has shown in the past that
UPR is activated in ﬁbroblast cells that derived from GD patients
and from carriers of GD mutations by evaluating increase in mRNA
and protein levels of BiP and CHOP, splicing of Xbp1 and phosphory-
lation of eIF2α [22]. In the present work additional ﬁbroblast lines,
that derived from untested GD patients, some with genotypes not
previously described, were studied for the activation of UPR. In addi-
tion, we examined EBV-transformed B-cells that derived from GD
patients. UPR activation was conﬁrmed in both cell types (Figs. 1
and 2, Tables 2 and 3). However, in EBV-transformed B-cells we
could not detect a signiﬁcant elevation in the level of phosphorylated
eIF2α (Fig. 2b, Table 3). We assume that this is the consequence of
the viral transformation and immortalization of these cells, giving
them replication ability by altering different gene expression path-
ways [38]. Given the positive results for UPR activation in EBV-trans-
formed GD derived B-cells, further analysis was performed onWBCs,
taken directly from GD patients, in order to validate activation of UPR
in these cells. BiP, CHOP and ATF4 mRNA levels were elevated in all
evaluated WBCs, highlighting UPR activation in GD patients.
We have previously shown that GBA1mRNA level increases in GD
derived cells in comparison to non GD cells [27]. In the present study
we conﬁrmed this elevation in GBA1mRNA level in GD derived ﬁbro-
blasts, EBV transformed B-cells and WBCs taken directly from patients016), http://dx.doi.org/10.1016/j.bcmd.2016.10.025
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er the GBA1 gene promoter contains elements that respond to this UPR
activation. Thapsigargin, a known ER stressor, elevated GBA1 transcrip-
tion in both normal and GD derived cells, conﬁrming that GBA1 tran-
scription is induced under activated UPR conditions (Fig. 5a).
We have previously shown, using CAT assays, that theGBA1 promot-
er has an active CCAAT binding site [29]. CHOP, also known asGADD153
(growth arrest and DNA damage inducible protein) is a nuclear protein
[39,40] of the CCAAT-enhancer binding protein (C/EBP) family of tran-
scription factors, originally characterized by their sequence speciﬁc
binding to CCAAT motifs in DNA [32]. CHOP transcription is activated
by several UPR-induced pathways [8,17]. It down regulates bcl2 and in-
duces transcription of GADD53 and ERO1α, which facilitate the dephos-
phorylation of eIF2α (promoting protein synthesis) and encodes an ER
oxidase, respectively, thus inducing cell death [41,42]. The possible di-
rect effect of CHOP on transcription of the GBA1 promoter was tested
using the dual luciferase assay. The results showed that the normal
but not the GBA1 promoter mutated in its CCAAT (CHOP) binding site,
is activated by CHOP (Fig. 5c).
The GBA1 promoter was evaluated in other studies [43,44].
Sidransky et al. sequenced the GBA1 promoter region to uncover con-
served sequences between species and regulatory elements within
this region. Several possible transcription factor families were iden-
tiﬁed [44].
In contrast to our results, McNeill et al. showed decreased GBA1
mRNA level in several ﬁbroblast samples that derived fromGD patients,
using an Affymetrix chip array and quantitative RT-PCR. An increase in
GBA1 mRNA levels was observed following treatment of these cells
with the pharmacological chaperone ambroxol [45].
Interestingly, our results also showed activation of the MAN2B and
ACP genes. This activation could have also resulted from UPR-mediated
CHOP activation. There is a CHOP binding site within the MANB gene
promoter, encoding lysosomal acid α-mannosidase, as well as a
CCAAT motif within the ACP gene promoter, encoding lysosomal acid
phosphatase (prediction tool: SABiosciences' Text Mining Application).
However, further studies are needed to conﬁrm this assumption.
To summarize, our results indicated activation of UPR in different
cell types derived from GD patients, highlighting the generality of thisPlease cite this article as: H. Braunstein, et al., Blood Cells Mol. Diseases (2process in this disease. They also showed that the UPR-regulated
CHOP transcription factor induces transcription of the GBA1 gene. Ele-
vated transcription of two other lysosomal enzymes, α-mannosidase
and acid phosphatase, was noted as well.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bcmd.2016.10.025.
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